Tests whether blood thinner apixaban is needed after heart rhythm ablation
Compares apixaban with no blood thinner in people with atrial fibrillation after ablation.
Plain-language title generated from the registry record
Registry title: AnticoaguLation ONE Year After Ablation of Atrial Fibrillation in Patients With Atrial Fibrillation (ALONE AF Study)
Key facts
- Where
- Seoul, South KoreaSee the site
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 19 and 80 years old?
Source: NCT04432220, who can take part
Where in South Korea
- Severance Cardiovascular Hospital Yonsei UniversitySeoul, South KoreaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Yonsei University
- Trial code
- NCT04432220
- Record updated
- 6 February 2023
- Original description
There has no evidence for the anticoagulation in patients who had undergone catheter ablation of atrial fibrillation, and has maintained sinus rhythm for more than 1 year. However, anticoagulation can increase the risk of bleeding, the study evaluating the role of oral anticoagulation is needed in this patients. This study will compare the efficacy and safety of non-vitamin K anticoagulants (apixaban) and no oral anticoagulation in patient with sinus rhythm one year after catheter ablation of AF.Read full original descriptionShow less
AnticoaguLation ONE Year After Ablation of Atrial Fibrillation in Patients With Atrial Fibrillation (ALONE AF Study)
There has no evidence for the anticoagulation in patients who had undergone catheter ablation of atrial fibrillation, and has maintained sinus rhythm for more than 1 year. However, anticoagulation can increase the risk of bleeding, the study evaluating the role of oral anticoagulation is needed in this patients. This study will compare the efficacy and safety of non-vitamin K anticoagulants (apixaban) and no oral anticoagulation in patient with sinus rhythm one year after catheter ablation of AF.
Inclusion: no recurrence of atrial fibrillation one year after catheter ablation of atrial fibrillation; CHA2DS2-VASc score >=1 (male) or >=2 (female); age: 19 to 80 years; non-valvular atrial fibrillation; those who consent the study; those who can be followed after enrollment.
Exclusion: Malignant tumors that have not been completely cured; Severe structural heart disease; Severe liver or kidney dysfunction; Thyroid dysfunction; Pregnant or breastfeeding women; Predicted survival is less than 12 months; Patients who do not understand the content of the study or disagree with it.